Welcome to the GradCafe

Hello!  Welcome to The GradCafe Forums.You're welcome to look around the forums and view posts.  However, like most online communities you must register before you can create your own posts.  This is a simple, free process that requires minimal information. Benefits of membership:

  • Participate in discussions
  • Subscribe to topics and forums to get automatic updates
  • Search forums
  • Removes some advertisements (including this one!)


  • Content count

  • Joined

  • Last visited


About MCF10A

  • Rank
    Espresso Shot

Profile Information

  • Gender
  • Application Season
    2017 Fall

Recent Profile Visitors

1,810 profile views
  1. I'm committed too! So see ya'll this fall
  2. Still 50:50 now. It's a tough one. Yeah I learned about HU housing options, but the $900/mo dorm room in Vandy is not as attractive as the $850/mo room in 2b apartment in Uppereast lol, and I want to live close to Longwood in G1. BTW good to see you here, I probably know who you are
  3. I'm facing a similar decision (Harvard BBS vs. GSK) so I can totally feel you. I pretty much agree with all of your pros and cons, and just want to add a few points: (1) GSK has many PIs doing comp bio/genomics work too. They recently added a new "computational and systems biology program", and recruited Dana Pe'er from Columbia to be the chair. Those PIs are doing amazing cancer related work (Berry Taylor, John Chodera, Christina Leslie, to name a few). (2) There are several faculty members in MIT Koch doing cancer immunology (their cancer immunology program has 10 faculty members according to the website). Their work might not be as transnational as those done by GSK researchers tho. (3) GSK is not necessarily cancer biology focused. They have a top-notch structure biology department (arguably the best in the nation), and many top-notch scientists doing non-cancer related developmental biology, stem cell biology, immunology and cell biology research. I think at the end of day, the major differences between GSK and MIT Biology are (1) translational vs. basic science research; (2) New York vs. Boston. The whole impression of the GSK program gives me is that they want to train the grad students to be ready to solve the problems in cancer clinics (clinical program, many many researchers doing translational research). Most of the cancer biologists at MIT (both Whitehead and Koch) focus on the deeper mechanism questions about cancer. Scientists at both places are doing outstanding science. Which aspect of cancer research interests you the most? As for New York vs. Boston, I haven't lived in either city, but I think both are awesome cities from my interview experience. The stipend should be similar at both places. The subsidized housing from GSK is a great deal, I don't know whether MIT provides subsidized housing too (Harvard doesn't so that's a big headache) Anyway, both are awesome programs and you really can't go wrong by choosing either
  4. Got accepted by UPenn CAMB Cancer Bio (tho I already emailed to withdraw my application)... I was told by the Adcom that there's a quota for international students, so I declined the offer immediately and hope some other intl student would get this slot soon. Good luck! Updates: just declined Weill Cornell PBSB and Duke Molecular Cancer Bio too. Hope will help folks on the wait list.
  5. Just got my schedule for a upcoming interview. So I'll be interviewing 6 (!!!!!) faculty members in one day. That's goona be a longggggggg day I bet...
  6. I'm a international applicant too. Grad school admission is indeed very hard for us because of funding issue. One thing I noticed is that research experience in the US+rec letter from PIs in the US can be the deal breaker for intl applicants, especially for the most competitive schools. Most of the intl students I met in my interviews have such experience (undergrad, summer research, exchange semester, thesis research, etc in the US). Good luck on your NYU Sackler and JHU and wish you can get into both!
  7. Based on my experience it shouldn't be a big deal. I thought I screwed up 2 interviews at 2 schools because I didn't answer the follow-up questions about my own research well. I felt really bad, but I ended up receiving very positive emails from those two interviewers and got into both schools. Thing are usually better than we thought, so don't worry too much!
  8. Me too! WOOOOO
  9. Big congrats! Gonna keep my finger crossed till next week or so
  10. Yeah I am suspecting the same. It's likely that we won't hear back till next Wed or so. What's even worse is that they MIGHT accept less people and put more people on wait list if they really want to control the size of the class.
  11. So another day of silence I guess?
  12. The yield rate of most schools should be lower than 50%. The yield rate at Harvard HILS (BBS, BIG, MCO, sys bio, chem bio....adding up together) last year is just 53%. So I would assume that the "20 interviewers for 13-15 coming class" situation is 90%+ post-interview acceptance rate.
  13. Me too! From both BCMB&PBSB
  14. Sloan Kettering acceptance!!! OMG can't describe my feeling right now